The 4th NextGen therapies of SJIA and MAS, part 4: it is time for IL-18 based trials in systemic juvenile idiopathic arthritis?
Pediatr Rheumatol Online J
; 21(Suppl 1): 79, 2024 Jan 05.
Article
en En
| MEDLINE
| ID: mdl-38183056
ABSTRACT
Since IL-18 has recently emerged as a biomarker associated with refractory disease course in SJIA, the focus of the discussion was the feasibility of the biomarker-driven drug development to SJIA. Overall, there was broad agreement on the conclusion that IL-18 is a uniquely specific biomarker for many of the subsets of SJIA most in need of new therapies, and it may define a class of diseases mediated by IL-18 excess. The consensus was that leveraging IL-18 remains our most promising "lead" for use in refractory SJIA as it may mechanistically explain the disease pathophysiology and lead to more targeted therapies.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Artritis Juvenil
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Revista:
Pediatr Rheumatol Online J
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos